Were Medicaments Without Side Effects Are Produced
As regards homeopathic medicinal products, the production starts from the mother tincture, a special macerate that can be obtained from plants, buds, biochemical compounds or biological substances, according to the ancient preparation procedures of the traditional Homeopathic Pharmacopoeia.
The mother tincture is gradually and constantly diluted under a laminar flow hood in class 100, usually using a water-alcohol solution as a solvent.
At each dilution a dynamization procedure is performed, i.e., one vertical shaking that transmits physical-chemical specifications to the solution. The activation process is standardized through the use of the SKA (Sequential Kinetic Activation) method, designed and developed by our researchers.
This technique ensures a full bioavailability of the active ingredients and improves their therapeutic properties.
Our production unit is authorized in accordance with international GMP standards. The production, control and storage of products take place in controlled particle contamination rooms, according to the strictest international standards.
We produce pellets, globules, and drops for oral use.
The production line is fully automated and produces both mono- and multi-component remedies.
All the qualitative, quantitative and microbiological controls required by the regulations on medicaments are carried out at our perfectly equipped production site. Guna, in an ideal synthesis between tradition and modernity, uses the most advanced scientific and technological breakthroughs in the production of its medicines, to give doctors and patients more and more effective medicaments without side effects, in compliance with the human being’s uniqueness.
In order to improve more and more the efficacy of our medicaments we are continuously developing basic and clinical researches. In the follow you may read some references of the publication supported by GUNA.
Published Papers
Year |
Authors |
Journal |
Research type |
Title |
Molecules or compounds |
---|---|---|---|---|---|
2009 |
Gariboldi S. et al. |
Pulmonary Pharmacology & Therapeutics |
In vivo basic research |
Low Dose oral administration of cytokines for treatment of allergic asthma. |
IL-12 IFN-γ |
2012 |
D’amico L. et al. |
Journal of Cancer Therapy |
Ex vivo basic research |
Low Dose of IL-12 stimulates T Cell response in cultures of PBMCs derived from Non Small Cell Lung Cancer Patients. |
IL-12 |
2013 |
Cardani D. et al. |
Gastroenterology Research |
In vivo basic research |
Oral administration of Interleukin-10 and Anti-IL-1 Antibody ameliorates experimental intestinal inflammation. |
IL-10 ANTI IL-1 |
2014 |
Roberti M. L. et al. |
Journal of Biological Regulatory & Homeostatic Agents |
Clinial Trial |
Immunomodulating treatment with Low Dose interleukin-4, interleukin-10 and interleukin-11 in psoriasis vulgaris |
IL-4 IL-10 |
2014 |
Radice E. et al. |
International Immunopharmacology |
Ex vivo basic research |
Low Doses of sequential-kinetic-activated interferon-gamma enhance the ex vivo cytotoxicity of peripheral blood natural killer cells from patients with early-stage colorectal cancer. A preliminary study. |
IFN-γ |
2015 |
Luchetti P. |
Minerva Medica Oftalmologica |
Observational retrospective study |
Increasing of visual function in patients with retinal atrophy treated with drugs of Low Dose Medicine. |
NT3 NT4 NGF |
2015 |
Barygina V. et al |
Journal of Dermatological Science |
In vitro basic research |
Treatment with Low Dose cytokines reduces oxidative-mediated injury in perilesional keratinocytes from vitiligo skin. |
IL-4 IL-10 FGF-β β-endorphin |
2015 |
Lotti T. et al |
Journal of Biological Regulatory & Homeostatic Agents |
Clinical Trial |
Vitiligo: successful combination treatment based on oral Low Dose cytokines and different topical treatments. |
IL-4 IL-10 ANTI IL-1 FGF-β |
2015 |
Radice E. et al |
Translational oncology |
Ex vivo basic research |
Enhancement of the immunomodulatory functions of ex vivo-generated dendritic cells from early-stage colon cancer patients by consecutive exposure to Low Doses of sequential kinetic activated IL-4 and IL-12. A preliminary study. |
IL-4 IL-12 |
2015 |
Lotti T. et al |
Der Hautarzt |
Observational retrospective study |
Successful combination treatment for Psoriasis with phototherapy and Low Dose Cytokines. |
IL-4 IL-10 ANTI IL-1 |
2015 |
Tessaro et al. |
Journal of Ovarian Research |
In vivo basic research |
Effect of oral administration of Low Dose follicle stimulating hormone on hyperandrogenized mice as amodel of polycystic ovary syndrome |
FSH |
2016 |
Barygina V. et al. |
Journal of Dermatological Science |
In vivo basic research |
Low Dose cytokines reduce oxidative stress in primary lesional fibroblasts obtained from psoriatic patients. |
IL-4 IL-10 FGF-β β-ENDORPHIN |
2016 |
Fiorito F. et al. |
Comparative Immunology, Microbiology and Infectious Diseases |
Veterinary study |
Clinical improvement in feline herpesvirus 1 infected cats by oral Low Dose of interleukin-12 plus interferon-gamma. |
IL-12 IFN-γ |
2016 |
Genazzani A. et al | Frontiers in Gynecological Endocrinology | Observational study | Pharmacological and Integrative Treatment of Stress-Induced Hypothalamic Amenorrhea. |
β-ESTRADIOL
|
2016 |
Uberti F. et al |
Cells Tissues Organs |
In vitro basic research |
Stimulation of the Non-neuronal Cholinergic System by Highly Diluted Acetylcholine in Keratinocytes.
|
ACH |
2017 |
Tessaro I. et al. |
J Reprod Infertil. |
In vivo basic research |
Ultra Low Dose of Follicle Stimulating Hormone and Progesterone attenuate the Severity of Polycystic Ovary Syndrome Features in a Hyperandrogenized Mouse Model. |
FSH PROGESTERON |
2017 |
Martin Martin L. S. et al. | Drud Design, Development and Therapy | Clinical Trial | An open randomized active-controlled clinical trial with Low Dose SKA cytokines versus DMARDs evaluating low disease activity maintenance in patients with rheumatoid arthritis. |
ANTI IL-1 IL-4 IL-10 |
2017 |
Carello R. et al. |
Italian Journal of Pediatrics |
Clinical Trial |
Long-term treatment with Low Dose Medicine in chronic childhood eczema. A double-blind two-stage randomized control trial. |
IL-12 IFN-γ |
2017 |
Castiglioni S. et al. |
International Journal of Molecular Sciences |
In vitro basic research |
Femtograms of Interferon-gamma Suffice to Modulate the Behavior of Jurkat Cells: A New Light in Immunomodulation. |
IFN-γ |
2018 |
Mancini F. et al. |
International Immunopharmacology |
In vitro basic research |
Low Dose SKA progesterone and Interleukin-10 modulate inflammatory pathway cytokines in endometriotic cell lines. |
IL-10 PROGESTERON |
2018 |
Uberti F. et al. |
Wound |
In vivo basic research |
Highly Diluited Acetylcholine Promotes Wound Repair in an In Vivo Model |
ACH |
2018 |
Tagliacarne S. C. et al. |
Immunology Letters |
Ex vivo basic research |
Low Dose multicomponent medication modulates humoral and cellular immune response in an ex-vivo study on children subjected to adenoid surgery. |
CITOMIX |
2020 |
Molinari C. et al. |
Brain Sciences |
In vitro and in animal model basic research |
The Role of BDNF on Aging-Modulation Markers. |
BDNF |
Submitted Papers
Year |
Authors |
Journal |
Research type |
Title |
Tested Molecules |
---|---|---|---|---|---|
2015 |
Galli E. et al. |
Submitted |
Clinical Trial |
Clinical and immunological evaluation of long-term treatment with Low Dose Medicine in pediatric population affected by chronic Atopic Dermatitis. Experimental randomized double-blind at two stages clinical trial. |
IL-12 IFN-γ |
2015 |
Fiorito F. et al |
Submitted |
Clinical Trial (veterinary) |
Clinical improvement in feline herpesvirus-1 infected cats by oral low doses of interleukin-12 and interferon-gamma. |
IL-12 IFN-γ |
2016 |
Migliore A. et al. |
Submitted |
Clinical Trial |
Treatment of Rheumatoid Arthritis with low dose SKA compared to standard treatment. |
Anti IL-1 IL-10 IL-4 |
Research Works On Going
Year |
Authors |
Journal |
Research type |
Title |
Food Supplement |
---|---|---|---|---|---|
2016 |
Matucci M. et al. |
Giornale Italiano di Ostetricia e Ginecologia |
Pilot Clinical Study |
Effectiveness of low dose SKA Anti IL-1 and IL-10 in Early Stage Symptomatic Osteoarthritis. |
Anti IL-1 IL-10 |
Research Works In Pipeline
Year |
Authors |
Journal |
Research type |
Title |
Food Supplement |
---|---|---|---|---|---|
2016 |
Torta R. et al. |
|
Clinical Trial |
Fibromyalgia and low grade inflammation: effectiveness and safety of low dose Interleukin-10 in a double blind randomized placebo controlled clinical trial. |
IL-10 |
2016 |
Masieri S. et al. |
|
Clinical Trial |
Effects of low dose SKA Interleukin-10 and TGF-Beta in nasal polyps. |
IL-10 TGF-β |
2016 |
De Cicco F. et al. |
|
In vivo and in vitro basic research |
Efficacy of low dose SKA interleukins and hormones in an animal model and cell cultures of Endometriosis. |
Anti IL-1 IL-10 Progesterone |